1. Volume 392, Issue 10164, Pages 2583-2594 (December 2018)
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial 
Prof Mark A Hull, FRCP, Kirsty Sprange, MSc, Trish Hepburn, BSc, Wei Tan, MSc, Aisha Shafayat, BSc, Prof Colin J Rees, FRCP, Gayle Clifford, BSc, Prof Richard F Logan, FRCP, Prof Paul M Loadman, PhD, Elizabeth A Williams, PhD, Diane Whitham, RN, Prof Alan A Montgomery, PhD 
The Lancet 
Volume 392, Issue 10164, Pages (December 2018)
DOI: /S (18)
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 1
Trial profile
EPA=eicosapentaenoic acid. NSAID=non-steroidal anti-inflammatory drug. PPI=proton-pump inhibitor.
The Lancet  , DOI: ( /S (18) )
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

3. Figure 2
RBC and rectal mucosal EPA concentrations by trial group and EPA formulation
Boxes represent the median and IQR. Whiskers represent 1·5 times the IQR with outlier values (individual datapoints) above and below the IQR. EPA=eicosapentaenoic acid. FFA=free-fatty acid. RBC=red blood cell. *Individuals randomly assigned to EPA–FFA or its placebo. †Individuals randomised to EPA–triglyceride or its placebo.
The Lancet  , DOI: ( /S (18) )
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions